Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Volker Schirrmacher. (2015) Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opinion on Biological Therapy 15:12, pages 1757-1771.
Read now
Read now
Volker Schirrmacher, Philippe Fournier & Peter Schlag. (2014) Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Review of Vaccines 13:1, pages 117-130.
Read now
Read now
Anne Flörcken, Joachim Kopp, Antje van Lessen, Kamran Movassaghi, Anna Takvorian, Korinna Jöhrens, Markus Möbs, Constanze Schönemann, Birgit Sawitzki, Karl Egerer, Bernd Dörken, Antonio Pezzutto & Jörg Westermann. (2013) Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer. Human Vaccines & Immunotherapeutics 9:6, pages 1217-1227.
Read now
Read now
Volker Schirrmacher & Philippe Fournier. (2010) Danger signals in tumor cells: a risk factor for autoimmune disease?. Expert Review of Vaccines 9:4, pages 347-350.
Read now
Read now
Udo Holtick & Michael von Bergwelt-Baildon. (2009) Post-transplant immunotherapy: combining cancer vaccines with hematopoietic stem cell transplantation. Expert Review of Vaccines 8:5, pages 519-523.
Read now
Read now
Articles from other publishers (13)
Mina Bahrololoumi Shapourabadi, Frank Momburg, Farzin Roohvand, Mostafa Jarahian, Nasir Mohajel, Arash Arashkia, Fatemeh Hajari Taheri, Maryam Abbasalipour & Kayhan Azadmanesh. (2021) Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy. International Immunopharmacology 96, pages 107762.
Crossref
Crossref
Jing-kang Wang, Bao-sheng Zhao, Min Wang, Chen-yue Liu, Ya-qi Li, Quan-tao Ma, Peng-fei Li, Tie-shan Wang, Chun-guo Wang & Yong-ming Zhou. (2020) Anti-tumor and Phenotypic Regulation Effect of Matrine on Dendritic Cells through Regulating TLRs Pathway. Chinese Journal of Integrative Medicine 27:7, pages 520-526.
Crossref
Crossref
Tara S Abraham & Adam E Snook. (2017) The swinging pendulum of cancer immunotherapy personalization. Personalized Medicine 14:3, pages 259-270.
Crossref
Crossref
Soodabeh Iranpour, Vahid Nejati, Nowruz Delirezh, Pouria Biparva & Sadegh Shirian. (2016) Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens. Journal of Experimental & Clinical Cancer Research 35:1.
Crossref
Crossref
Diahnn F Campbell, Rebecca Saenz, Ila S Bharati, Daniel Seible, Liangfang Zhang, Sadik Esener, Bradley Messmer, Marie Larsson & Davorka Messmer. (2015) Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. Breast Cancer Research 17:1.
Crossref
Crossref
Philippe Fournier & Volker Schirrmacher. (2012) Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer. BioDrugs 27:1, pages 35-53.
Crossref
Crossref
Jun Yan, Zi-Yan Wang, Hong-Zhen Yang, Han-Zhi Liu, Su Mi, Xiao-Xi Lv, Xiao-Ming Fu, Hui-Min Yan, Xiao-Wei Zhang, Qi-Min Zhan & Zhuo-Wei Hu. (2011) Timing Is Critical for an Effective Anti-Metastatic Immunotherapy: The Decisive Role of IFNγ/STAT1-Mediated Activation of Autophagy. PLoS ONE 6:9, pages e24705.
Crossref
Crossref
J Westermann, A Flörcken, G Willimsky, A van Lessen, J Kopp, A Takvorian, K Jöhrens, A Lukowsky, C Schönemann, B Sawitzki, H Pohla, R Frank, B Dörken, D J Schendel, T Blankenstein & A Pezzutto. (2010) Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Therapy 18:4, pages 354-363.
Crossref
Crossref
Sarfraz Ahmad, Garrett Casey, Paul Sweeney, Mark Tangney & Gerald C O'Sullivan. (2010) Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genetic Vaccines and Therapy 8:1.
Crossref
Crossref
Joshua D. BrodyWeiyun Z. AiDebra K. CzerwinskiJames A. TorchiaMia LevyRanjana H. AdvaniYoun H. KimRichard T. HoppeSusan J. KnoxLewis K. ShinIrene WapnirRobert J. TibshiraniRonald Levy. (2010) In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. Journal of Clinical Oncology 28:28, pages 4324-4332.
Crossref
Crossref
Corbin Clawson, Chien-Tze Huang, Diahnn Futalan, Daniel Martin Seible, Rebecca Saenz, Marie Larsson, Wenxue Ma, Boris Minev, Fiona Zhang, Mihri Ozkan, Cengiz Ozkan, Sadik Esener & Davorka Messmer. (2010) Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell–stimulatory capacity. Nanomedicine: Nanotechnology, Biology and Medicine 6:5, pages 651-661.
Crossref
Crossref
T Pencavel, R Seth, A Hayes, A Melcher, H Pandha, R Vile & K J Harrington. (2010) Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?. Gene Therapy 17:8, pages 949-960.
Crossref
Crossref
Philippe Fournier & Volker Schirrmacher. (2010) Tumor Antigen-Dependent and Tumor Antigen-Independent Activation of Antitumor Activity in T Cells by a Bispecific Antibody-Modified Tumor Vaccine. Clinical and Developmental Immunology 2010, pages 1-12.
Crossref
Crossref